Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: Britain’s legal bookmakers reported high interest Tuesday in the names Alexander, James and Arthur. They also noted speculation about the name Spencer, the maiden name of Harry’s late mother, Princess Diana. Royal babies usually have a string of names, opening the way for endless betting possibilities. “Following a flurry of bets last evening, Alexander is now the new favorite at the top of our name betting and the one we are fearing the most,” said John Hill of the Coral betting agency. Alexander has 4/1 odds at Coral, while Arthur is 6/1 and Albert, James and Spencer are all 8/1. Choosing Spencer as a first or middle name is seen as a way for Harry to honor Diana, who died in a Paris car crash in 1997 when he was only 12. Before he married Meghan last year, Harry spoke about his desire to pay tribute to his mother’s memory during the wedding ceremony. Others believe Meghan could choose a name that reflects her American biracial heritage. One Twitter user suggested Marvin — for the late singer Marvin Gaye. The infant, known only as Baby Sussex for the moment, was born Monday at 5:26 a.m. at a yet-undisclosed location. In a gushing announcement of the birth, Harry said he and Meghan are “thinking” about names and hinted that an announcement might be made Wednesday or shortly thereafter. The couple is also expected to pose with their newborn or release a photo on their Instagram account at some time and to publicly name godparents for the child. The new arrival is the eighth great-grandchild of Queen Elizabeth II, who smiled when asked about the baby’s arrival at a luncheon Tuesday. Asked if life is good, the 93-year-old monarch said: “Yes, thank you.” The baby boy is the first of her great-grandchildren to have an American parent. His mother Meghan is the daughter of a white man and a black woman, bringing a biracial heritage to the House of Windsor. Trevor Phillips, a retired black broadcaster who headed Britain’s Equality and Human Rights Commission, wrote an open letter to the royal baby, saying his arrival reflects British society’s more open attitude nowadays and the increasing inclusiveness of the royal family. “This is a family that lives the reality of a multicultural world daily,” he said. “It’s their job: to interact with people of different backgrounds to themselves on behalf of the nation, and to treat them all with respect. I have to tell you, they are pretty good at it.” He went on to tell the baby: “Whether you like it or not, you’re going to have a special place in the nation’s heart.” Prince William, Harry’s older brother, joked Tuesday that he will be glad “to welcome my own brother into the sleep deprivation society that is parenting!” “Obviously thrilled, absolutely thrilled, and obviously looking forward to seeing them in the next few days when things have quietened down,” William told reporters. The birth produced a moment of high drama likely to be replayed for the rest of Harry’s life. The prince, who has battled mental health challenges since the abrupt loss of his mother at a young age, emerged with the world’s most satisfied grin Monday afternoon to announce the birth of his son before TV news cameras. “We’re both absolutely thrilled and so grateful for all the love and support from everybody out there. It’s been amazing, so we just wanted to share this with everybody,” the normally press-shy royal gushed. Harry also burnished his feminist credentials — and paid tribute to mothers around the world — after witnessing the birth. “It’s been the most amazing experience I could ever have possibly imagined,” he said. “How any woman does what they do is beyond comprehension.” ___ Read all Associated Press coverage of the latest royal baby at https://www.apnews.com/RoyalBaby Claim: Will new royal baby’s name honor Princess Diana? Stay tuned.
[A]: Britons love to lay down their bets — and with the birth of a healthy baby boy for Meghan, the Duchess of Sussex, and Prince Harry, it’s time to focus on boys’ names.


[Q]: Paragraph: Nigeria has reported 317 confirmed cases in two months, more than the total for all of last year. The World Health Organization says there are 20 suspected cases across the border in Benin. Nigeria has reported 72 deaths so far. There is no vaccine for the hemorrhagic fever, which is transmitted through the bodily fluids of sick people. Humans also can contract the disease by coming into contact with food contaminated by rat excrement. Those with the disease initially present with high fever but in extreme cases can later suffer bleeding from the nose and mouth. Claim: Nigeria reports record high Lassa fever cases with 317.
[A]: Health authorities say a Lassa fever outbreak in Nigeria has reached a record high and there are suspected cases in neighboring Benin as well.


[Q]: Paragraph: Although Pfizer continues to test the drug, called dacomitinib, in another Phase III study, hopes for its success have now largely faded, according to ISI Group analyst Mark Schoenebaum. “We believe consensus expectations (for the drug) will be close to zero given today’s readout” of unsuccessful trial results, Schoenebaum said in a research note. In one of the failed trials, called ARCHER 1009, patients given Pfizer’s once-daily pill did not show improved survival without the cancer worsening, compared with Roche Holding AG’s widely used Tarceva (erlotinib). Tarceva is the current standard of care in patients with mutated forms of a protein called Epidermal Growth Factor Receptor (EGFR). The protein plays a role in normal regulation of cell growth, but when mutated is believed to cause cells to proliferate and thereby help spur various types of cancer. Dacomitinib is designed to block several types of Epidermal Growth Factor receptors, while Tarceva and similar treatments for lung cancer target only one type of receptor. Cowen and Co had forecast annual sales of $500 million by 2020 for dacomitinib, if it were approved for lung cancer. That would make it a moderate-sized product for Pfizer, the largest U.S. drugmaker, which has annual revenue of $50 billion. Schoenebaum said there has been little investor interest in the drug and that Wall Street had expected it to generate annual sales of only $300 million by 2018. The second failed trial, named BR.26, involved patients that previously had failed to benefit from chemotherapy as well as from treatment with an EGFR inhibitor. Overall survival of patients taking the Pfizer drug was not prolonged in the study, compared with patients given a placebo. Pfizer said adverse events seen with dacomitinib were consistent with those seen in smaller earlier studies. In the meantime, Pfizer said dacomitinib is also being tested in a third late-stage trial, called ARCHER 1050, among patients with advanced non-small cell lung cancer who have not received prior treatment. The study will compare dacomitinib with Iressa (gefitinib), an EGFR inhibitor sold by AstraZeneca Plc. Results from that study are expected in 2015. Pfizer shares were little changed in morning trading on the New York Stock Exchange. Claim: Pfizer lung cancer drug fails in two large studies.
[A]:
Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the most common form of the disease.